Halozyme Therapeutics Newswire

Halozyme Therapeutics Newswire

Comprehensive Real-Time News Feed for Halozyme Therapeutics.

Results 1 - 20 of 120 in Halozyme Therapeutics

  1. Halozyme Therapeutics, Inc. (HALO) Given Consensus Recommendation of "Hold" by AnalystsRead the original story w/Photo

    Wednesday | AmericanBankingNews.com

    Halozyme Therapeutics, Inc. has earned a consensus rating of "Hold" from the seven analysts that are covering the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company.

    Comment?

  2. Halozyme Therapeutics, Inc. (HALO) Shares Sold by Fmr LLCRead the original story

    Saturday Mar 18 | IntersportsWire

    Fmr LLC cut its position in shares of Halozyme Therapeutics, Inc. by 13.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,766,382 shares of the biopharmaceutical company's stock after selling 1,040,093 shares during the period.

    Comment?

  3. Monaco Vs. Manchester City Live StreamRead the original story w/Photo

    Wednesday Mar 15 | The Oak Ridge Observer

    ... of $-0.18/share and a Low EPS of $-0.27/share. Franklin Resources Inc. owned approximately 0.81% of Halozyme Therapeutics worth $10,214,000 as of its most recent SEC filing. Investigators believe the pickup, which was heading westbound on the ...

    Comment?

  4. Former President Barack Obama Reveals His 2017 March Madness BracketRead the original story

    Wednesday Mar 15 | The Oak Ridge Observer

    ... of $-0.18/share and a Low EPS of $-0.27/share. Franklin Resources Inc. owned approximately 0.81% of Halozyme Therapeutics worth $10,214,000 as of its most recent SEC filing. Also, Kurtulmus recommended that the Turkish Parliament abolish agreements ...

    Comment?

  5. Halozyme Therapeutics, Inc.Read the original story

    Wednesday Mar 15 | The Oak Ridge Observer

    After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. Franklin Resources Inc. owned approximately 0.81% of Halozyme Therapeutics worth $10,214,000 as of its most recent SEC filing.

    Comment?

  6. White House says Trump paid $38 million in taxes in 2005Read the original story

    Wednesday Mar 15 | The Oak Ridge Observer

    ... of $-0.18/share and a Low EPS of $-0.27/share. Franklin Resources Inc. owned approximately 0.81% of Halozyme Therapeutics worth $10,214,000 as of its most recent SEC filing. According to the companies, the AI self-driving vehicle system will be ...

    Comment?

  7. Nvidia Forges Alliance To Bring Self-Driving Cars To The MassesRead the original story

    Wednesday Mar 15 | The Oak Ridge Observer

    ... of $-0.18/share and a Low EPS of $-0.27/share. Franklin Resources Inc. owned approximately 0.81% of Halozyme Therapeutics worth $10,214,000 as of its most recent SEC filing. The American telecom conglomerate AT&T will be launching 5G wireless ...

    Comment?

  8. Trexquant Investment LP Acquires Shares of 35,009 Halozyme Therapeutics, Inc.Read the original story w/Photo

    Thursday Mar 2 | Daily Political

    Trexquant Investment LP acquired a new stake in shares of Halozyme Therapeutics, Inc. during the fourth quarter, Holdings Channel reports. The fund acquired 35,009 shares of the biopharmaceutical company's stock, valued at approximately $346,000.

    Comment?

  9. Halozyme Reports Fourth Quarter And Full Year 2016 Financial ResultsRead the original story

    Tuesday Feb 28 | BioSpace

    , Feb. 28, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results and recent highlights for the fourth quarter and full year ...

    Comment?

  10. Halozyme Therapeutics' (HALO) CEO Helen Torley on Q4 2016 Results - Earnings Call TranscriptRead the original story w/Photo

    Tuesday Feb 28 | Seeking Alpha

    Good afternoon and welcome to the Halozyme Therapeutics Fourth Quarter 2016 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

    Comment?

  11. Get Ready: Biotech Is Ready To Break OutRead the original story w/Photo

    Tuesday Feb 28 | Seeking Alpha

    ... So what small and mid-cap biotech stocks do I see with the most potential in the coming weeks? Halozyme Therapeutics ( HALO ) is one of my favorite small cap biotech setups right now. The stock has peaked at just over $14 per share twice since last ...

    Comment?

  12. Halozyme Therapeutics, Inc. (HALO) to Release Earnings on TuesdayRead the original story w/Photo

    Monday Feb 27 | AmericanBankingNews.com

    Halozyme Therapeutics, Inc. will post its Q416 quarterly earnings results on Tuesday, February 28th. Analysts expect Halozyme Therapeutics to post earnings of per share and revenue of $37.94 million for the quarter.

    Comment?

  13. Halozyme Therapeutics, Inc. (HALO) Set to Announce Quarterly Earnings on TuesdayRead the original story w/Photo

    Friday Feb 24 | IntersportsWire

    Halozyme Therapeutics, Inc. will be announcing its Q416 earnings results on Tuesday, February 28th. Analysts expect the company to announce earnings of per share and revenue of $37.94 million for the quarter.

    Comment?

  14. Oxford Asset Management Takes Position in Halozyme Therapeutics, Inc.Read the original story w/Photo

    Feb 21, 2017 | IntersportsWire

    Oxford Asset Management purchased a new stake in shares of Halozyme Therapeutics, Inc. during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission . The institutional investor purchased 177,311 shares of the biopharmaceutical company's stock, valued at approximately $1,752,000.

    Comment?

  15. Halozyme Therapeutics, Inc. (HALO) Receives Average Rating of "Hold" from AnalystsRead the original story w/Photo

    Feb 20, 2017 | AmericanBankingNews.com

    Shares of Halozyme Therapeutics, Inc. have earned an average recommendation of "Hold" from the nine ratings firms that are currently covering the stock. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company.

    Comment?

  16. J. Goldman & Co LP Reduces Stake in Halozyme Therapeutics, Inc.Read the original story w/Photo

    Feb 14, 2017 | Daily Political

    J. Goldman & Co LP lowered its position in Halozyme Therapeutics, Inc. by 4.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission . The fund owned 269,176 shares of the biopharmaceutical company's stock after selling 13,724 shares during the period.

    Comment?

  17. MabVax Therapeutics Studies Lead Investigational Drug MVT-5873 With Halozyme PEGPH20Read the original story

    Feb 12, 2017 | BioSpace

    PEGPH20 is currently in phase III clinical development for metastatic pancreatic cancer and in phase I clinical trials for non-small cell lung cancer, gastric cancer, and metastatic breast cancer. Results from the preclinical study were positive demonstrating improvement in accumulation of MVT-5873 on tumors in an animal model of pancreatic cancer when administered in sequence with PEGPH20.

    Comment?

  18. BRIEF-First Eagle Investment Management LLC reports a 5.94 pct...Read the original story w/Photo

    Feb 6, 2017 | Reuters

    First Eagle Investment Management LLC reports a 5.94 pct passive stake in Halozyme Therapeutics as of Dec 31 - SEC Filing * First Eagle Investment Management LLC reports a 5.94 percent passive stake in Halozyme Therapeutics Inc as of December 31, 2016 - SEC Filing Source text: [ bit.ly/2kkBxab ] Further company coverage: JAKARTA, Feb 7 Indonesia will hold a court hearing on Tuesday into a billion-dollar dispute between Goldman Sachs and a local tycoon, who says the Wall Street giant's unit unlawfully sold shares he owned, in the latest test for the country's legal system.

    Comment?

  19. KKR to merge hedge fund Prisma with PAAMCO to form new investment firmRead the original story w/Photo

    Feb 6, 2017 | Reuters

    ... by Savio D'Souza) BRIEF-First Eagle Investment Management LLC reports a 5.94 pct passive stake in Halozyme Therapeutics as of Dec 31 - SEC Filing * First Eagle Investment Management LLC reports a 5.94 percent passive stake in Halozyme Therapeutics ...

    Comment?

  20. BlackRock Institutional Trust Company N.A. Acquires 159,654 Shares of ...Read the original story w/Photo

    Jan 30, 2017 | Daily Political

    BlackRock Institutional Trust Company N.A. raised its stake in Halozyme Therapeutics, Inc. by 5.6% during the third quarter, according to its most recent disclosure with the SEC. The firm owned 3,005,011 shares of the biopharmaceutical company's stock after buying an additional 159,654 shares during the period.

    Comment?